Summary

The once-daily, oral, 12-week regimen using a single tablet combination of sofosbuvir (SOF; 400 mg) and ledipasvir (LDV; 90 mg) with or without ribavirin produces high sustained virologic response 12 weeks after conclusion of treatment in hepatitis C virus (HCV)-infected patients with compensated cirrhosis. This article discussed a study comprised of pooled data from the LONESTAR, ELECTRON and ELECTRON-2, ION-1 and ION-2, and SIRIUS trials.